Cargando…
The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer
OBJECTIVE: Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate v...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745166/ https://www.ncbi.nlm.nih.gov/pubmed/36523968 http://dx.doi.org/10.3389/fonc.2022.1049970 |
_version_ | 1784849088250904576 |
---|---|
author | Cherifi, François Lefevre Arbogast, Sophie Font, Jonaz Abdeddaim, Cyril Becourt, Stephanie Penel, Nicolas Coquan, Elodie Lequesne, Justine Gidron, Yori Joly, Florence |
author_facet | Cherifi, François Lefevre Arbogast, Sophie Font, Jonaz Abdeddaim, Cyril Becourt, Stephanie Penel, Nicolas Coquan, Elodie Lequesne, Justine Gidron, Yori Joly, Florence |
author_sort | Cherifi, François |
collection | PubMed |
description | OBJECTIVE: Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate variability (HRV), may predict poor cancer prognosis. We aimed to examine the prognostic value of HRV in OC. METHODS: This bicentric retrospective study included patients diagnosed with serous OC FIGO stage ≥IIB, between January 2015 and August 2019, with electrocardiograms (ECG) available around diagnosis. HRV was measured from ECG using the time domain parameter of standard deviation of all normal-to-normal heartbeat intervals (SDNN). Optimal SDNN cut-off was determined using the Youden index criteria of time-dependent ROC curves. We used multivariate cox proportional hazard models to investigate the association between HRV and overall survival (OS), while adjusting for well-known OC prognostic factors. RESULTS: The 202 patients included were 65.7 years-old on average, 93% had stage FIGO IIIC/IV, 56% had complete surgical resection. Median OS was 38.6 months [95%CI:34.4-47.4]. The median SDNN was 11.1ms, with an optimal cut-off of 10ms to predict OS. OS was shorter for patients with low HRV compared to high HRV (26.4 vs 45.1 months; p<0.001). In multivariate analysis, HRV remained an independent prognostic factor with a two-fold higher risk of death among patients with low SDNN compared to those with high SDNN (HR=2.03, 95%CI=1.35-3.06, p<0.001). CONCLUSION: Low HRV, was associated with worse OS in OC patients, supporting previous studies on the prognostic role of HRV in cancer. If replicated in prospective studies, vagal nerve activity may be a new therapeutic target in OC. |
format | Online Article Text |
id | pubmed-9745166 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97451662022-12-14 The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer Cherifi, François Lefevre Arbogast, Sophie Font, Jonaz Abdeddaim, Cyril Becourt, Stephanie Penel, Nicolas Coquan, Elodie Lequesne, Justine Gidron, Yori Joly, Florence Front Oncol Oncology OBJECTIVE: Identifying new modifiable prognostic markers is important for ovarian cancer (OC). Low parasympathic activity is associated with inflammation, oxidative stress and sympathetic nervous system activation. Previous studies reported that low vagal nerve activity, measured by low heart rate variability (HRV), may predict poor cancer prognosis. We aimed to examine the prognostic value of HRV in OC. METHODS: This bicentric retrospective study included patients diagnosed with serous OC FIGO stage ≥IIB, between January 2015 and August 2019, with electrocardiograms (ECG) available around diagnosis. HRV was measured from ECG using the time domain parameter of standard deviation of all normal-to-normal heartbeat intervals (SDNN). Optimal SDNN cut-off was determined using the Youden index criteria of time-dependent ROC curves. We used multivariate cox proportional hazard models to investigate the association between HRV and overall survival (OS), while adjusting for well-known OC prognostic factors. RESULTS: The 202 patients included were 65.7 years-old on average, 93% had stage FIGO IIIC/IV, 56% had complete surgical resection. Median OS was 38.6 months [95%CI:34.4-47.4]. The median SDNN was 11.1ms, with an optimal cut-off of 10ms to predict OS. OS was shorter for patients with low HRV compared to high HRV (26.4 vs 45.1 months; p<0.001). In multivariate analysis, HRV remained an independent prognostic factor with a two-fold higher risk of death among patients with low SDNN compared to those with high SDNN (HR=2.03, 95%CI=1.35-3.06, p<0.001). CONCLUSION: Low HRV, was associated with worse OS in OC patients, supporting previous studies on the prognostic role of HRV in cancer. If replicated in prospective studies, vagal nerve activity may be a new therapeutic target in OC. Frontiers Media S.A. 2022-11-29 /pmc/articles/PMC9745166/ /pubmed/36523968 http://dx.doi.org/10.3389/fonc.2022.1049970 Text en Copyright © 2022 Cherifi, Lefevre Arbogast, Font, Abdeddaim, Becourt, Penel, Coquan, Lequesne, Gidron and Joly https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Cherifi, François Lefevre Arbogast, Sophie Font, Jonaz Abdeddaim, Cyril Becourt, Stephanie Penel, Nicolas Coquan, Elodie Lequesne, Justine Gidron, Yori Joly, Florence The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
title | The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
title_full | The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
title_fullStr | The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
title_full_unstemmed | The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
title_short | The promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
title_sort | promising prognostic value of vagal nerve activity at the initial management of ovarian cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745166/ https://www.ncbi.nlm.nih.gov/pubmed/36523968 http://dx.doi.org/10.3389/fonc.2022.1049970 |
work_keys_str_mv | AT cherififrancois thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT lefevrearbogastsophie thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT fontjonaz thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT abdeddaimcyril thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT becourtstephanie thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT penelnicolas thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT coquanelodie thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT lequesnejustine thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT gidronyori thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT jolyflorence thepromisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT cherififrancois promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT lefevrearbogastsophie promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT fontjonaz promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT abdeddaimcyril promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT becourtstephanie promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT penelnicolas promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT coquanelodie promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT lequesnejustine promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT gidronyori promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer AT jolyflorence promisingprognosticvalueofvagalnerveactivityattheinitialmanagementofovariancancer |